Neuroone Medical Technologies (NMTC) Non-Current Deferred Tax Liability (2021 - 2022)
Neuroone Medical Technologies' (NMTC) quarterly Non-Current Deferred Tax Liability came in at $140538.0 in Q3 2022, up 118.94% on a YoY basis from $64189.0 in Q3 2021, and up 118.94% quarter-over-quarter from $64189.0 in Q3 2021.
Powered by 
Analysis
Neuroone Medical Technologies (NMTC) Non-Current Deferred Tax Liability (2021 - 2022) Analysis & Trends
Neuroone Medical Technologies (NMTC) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $140538.0 the latest figure, recorded in Q3 2022.
- For the quarter ending Q3 2022, Non-Current Deferred Tax Liability rose 118.94% year-over-year to $140538.0; the trailing twelve-month figure through Sep 2022 stood at $140538.0 (up 118.94% YoY), and the FY2022 full-year result was $140538.0, up 118.94% from the prior year.
- Non-Current Deferred Tax Liability climbed to $140538.0 in Q3 2022 per NMTC's latest filing, from $64189.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $140538.0 in Q3 2022 and bottomed at $64189.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Neuroone Medical Technologies | 14.33 Mn | 12.29 Mn | 1.18 Mn |